Zoledronic acid seems to reduce risk of repeat breaks and death after hip fracture

doi:10.1136/bmj.39343.363600.DB

BMJ 2007;335:584-585 (22 September), doi:10.1136/bmj.39343.363600.DB

News

Zoledronic acid seems to reduce risk of repeat breaks and death after hip fracture

Janice Hopkins Tanne

New York

The first 150 words of the full text of this article appear below.

Patients who had undergone surgical repair of hip fracture aftera minor fall and who were then given an annual intravenous infusionof zoledronic acid were less likely to have a new vertebralfracture, to have a new non-vertebral fracture, or to die, anew study has found.

The international, double blind, placebo controlled study wasreleased early by the New England Journal of Medicine (doi:10.1056/NEJMoa074941). The trial was sponsored by Novartis,the manufacturer of the drug, which is marketed as Reclast inthe United States and Aclasta in the United Kingdom.

Just over a third of patients aged over 50 who have had a hipfracture are likely to die within two years, write the authorsof an accompanying editorial (doi: 10.1056/NEJMe078192), andmany who survive "do not regain their prefracture level of mobilityand thereby endure loss of independence and deterioration inhealth-related quality of . . . [Full text of this article]

Add to CiteULike CiteULike Add to Complore Complore Add to Connotea Connotea Add to Del.icio.us Del.icio.us Add to Digg Digg Add to Reddit Reddit Add to Technorati Technorati What's this?